Status:
COMPLETED
S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation
Lead Sponsor:
Pfizer
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Evaluate efficacy and safety of Indobufen v. Aspirin in preventing thromboembolic events in patients at high risk of CV events such as patients suffering from nonrheumatic atrial fibrillation.
Eligibility Criteria
Inclusion
- Chronic or paroxysmal non rheumatic atrial fibrillation with cardioembolic risk factors: hypertension, ischemic cardiopathy, Congestive Heart Failure, diabetes mellitus
Exclusion
- Clinically relevant organ disease
- creatinine clearance \< 30 ml/min
- gastric or duodenal ulcer
- severe anaemia or poliglobulia
Key Trial Info
Start Date :
December 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
1372 Patients enrolled
Trial Details
Trial ID
NCT00244426
Start Date
December 1 2000
End Date
April 1 2008
Last Update
December 19 2018
Active Locations (132)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Lagosanto, FE, Italy, 44023
2
Pfizer Investigational Site
Perugia, PG, Italy, 06100
3
Pfizer Investigational Site
Perugia, PG, Italy, 06123
4
Pfizer Investigational Site
Poggibonsi, SI, Italy, 53036